Clinical trial · Observational
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
Description of Relugolix Use in Patients With Prostate Cancer: An Analysis of National Veterans Affairs Health Care Network Data
NCT06462014CI-TRIAL-00098837completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Relugolix | Drug | Relugolix | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Relugolix patients
- description
- Patients who have initiated relugolix
- interventionNames
- Drug: Relugolix
Primary outcomes (11)
- measure
- Number of Participants According to Geographic Region
- timeFrame
- Baseline period = Up to 1 year prior to index date; available data observed retrospectively over 178 days in this study
- description
- The number of participants according to geographic regions of the United States (South, West, Northeast and Midwest) as documented during baseline period were reported in this outcome measure. Baseline period was 1 year prior to index date; index date was the initiation date of relugolix (anytime between 18-Dec-2020 to 31-Dec-2023) on or after the first observed prostate cancer diagnosis.
- measure
- Number of Participants According to Index Year
- timeFrame
- At Index date (anytime between 18-Dec-2020 to 31-Dec- 2023 [approximately 3 years]; available data observed retrospectively over 178 days in this study
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male with ≥ 1 diagnosis for PC * Had ≥ 2 prescriptions of relugolix on or after the first observed PC diagnosis. * Index date: the initiation date of relugolix * At least 18 years old at the index date Exclusion Criteria: * had surgical castration (bilateral orchiectomy) any time before the index date
References
Publications (1)
- DERIVEDFreedland SJ, Ramaswamy K, Kavati A, Gao W, Razo JF, Cole M, Li B, Yang H, Guo T, Chen G, McKay RR. Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration. Adv Ther. 2025 Dec;42(12):6278-6294. doi: 10.1007/s12325-025-03390-6. Epub 2025 Nov 1. PMID 41174189